FMP
Quince Therapeutics, Inc.
QNCX
NASDAQ
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
0.985 USD
0.0251 (2.55%)
About
ceo
Dr. Dirk Thye M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.quincetx.com
exchange
NASDAQ
Description
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
CIK
0001662774
ISIN
US22053A1079
CUSIP
22053A107
Address
601 Gateway Blvd
Phone
415 910 5717
Country
US
Employee
32
IPO Date
May 9, 2019
Key Executives
